ZVRA
NASDAQ
US
Zevra Therapeutics, Inc. - Common Stock
$9.40
▼ $-0.01
(-0.11%)
Vol 587K
10
Quality Score
ok
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$504.4M
P/E
14.3
ROE
42.7%
Margin
41.9%
D/E
46.04
Beta
1.00
52W
$6–$13
Wall Street Consensus
15 analysts · Apr 20265
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
93.3%
Buy Rating
Price Chart
Similar Stocks
LXRX
Lexicon Pharmaceuticals Inc
$417.9M
ESPR
Esperion Therapeutics Inc
$884.5M
LBRX
LB Pharmaceuticals Inc
$563.2M
CRMD
CorMedix Inc
P/E 5.6
$916.3M
FULC
Fulcrum Therapeutics Inc
$746.1M
ACRS
Aclaris Therapeutics Inc
$326.1M
AQST
Aquestive Therapeutics Inc
$788.1M
AVIR
Atea Pharmaceuticals Inc
$278.9M
CTNM
Contineum Therapeutics Inc
$417.5M
Earnings
Beat rate: 75.0%
Next Report
May 11, 2026
EPS Estimate: $0.09
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $0.09 | — | — |
| Dec 2025 | $0.05 | $0.21 | +$0.16 |
| Sep 2025 | $-0.04 | $-0.01 | +$0.03 |
| Jun 2025 | $1.53 | $1.21 | $-0.32 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 4.0% | -201.1% | 4.0% | 4.0% | 42.7% | 42.7% |
| P/E (TTM) | 182.20 | — | 153.50 | 236.73 | 13.43 | 14.28 |
| Net Margin | 288.7% | -226.6% | 4.3% | 4.3% | 41.9% | 41.9% |
| Gross Margin | 93.8% | 84.4% | 89.7% | 89.7% | 93.9% | 93.9% |
| D/E Ratio | 51.77 | 146.48 | 51.77 | 51.77 | 46.04 | 46.04 |
| Current Ratio | 7.85 | 3.02 | 7.85 | 7.85 | 8.62 | 8.62 |
Key Ratios
ROA (TTM)
16.1%
P/S (TTM)
5.98
P/B
11.2
EPS (TTM)
$0.59
CF/Share
$-1.15
Rev Growth 3Y
-6.2%
52W High
$13.16
52W Low
$6.19
$6.19
52-Week Range
$13.16
How does ZVRA compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ZVRA valuation vs Pharmaceuticals peers
P/E ratio
14.3
▼
36%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
6.0
▲
21%
above
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
11.2
▲
429%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ZVRA profitability vs Pharmaceuticals peers
ROE
42.7%
▲
179%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
41.9%
▲
188%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
93.9%
▲
37%
above
peers
(68.3%)
vs Peers
vs Industry
Below avg
ROA
16.1%
▲
143%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
ZVRA financial health vs Pharmaceuticals peers
D/E ratio
46.0
▲
2890%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
8.6
▲
157%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.0
▲
6%
above
peers
(0.9)
vs Peers
vs Industry
Less volatile
ZVRA fundamentals radar
ZVRA
Peer median
Industry
ZVRA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ZVRA vs peers: key metrics
Latest News
No related news yet